Searchable abstracts of presentations at key conferences in endocrinology

ea0087p4 | Poster Presentations | UKINETS2022

Exploring the potential benefit of epigenetic modification: The LANTana trial, an open label, single arm, phase Ib study to evaluate the effect of pre-treatment with ASTX727 (a demethylating agent) followed by Lutathera (177Lu-DOTATATE) in patients with progressive, metastatic neuroendocrine tumours (NETs)

Murphy Ravindhi , Chander Gurvin , Sharma Rohini

Background: Neuroendocrine tumours (NET) are rare cancers arising from cells of the neuroendocrine system and frequently present with advanced disease. They are characterised by the presence of somatostatin receptors (SSTR) on the tumour surface. The presence of SSTR are associated with the inhibition of NET proliferation and have formed the basis of peptide receptor radionuclide therapy (PRRT), such as Lutathera. PRRT relies on SSTR tumour expression and patients without this...

ea0052p42 | (1) | UKINETS2017

Therapeutic options in metastatic phaeochromocytomas

Mills Edouard , Dina Roberto , Palazzo Fausto , Sharma Rohini , Wernig Florian

Phaeochromocytomas are rare neuroendocrine tumours. Prediction of aggressive tumour behaviour remains a major challenge. We report a 68-year-old female who was found to have a locally arising colonic adenocarcinoma on biopsies. Staging also identified a 10.7 cm right adrenal lesion and work-up revealed markedly raised urinary metanephrines and positive MIBG imaging. The MDT decision was to first remove the colonic cancer with appropriate alpha blockade. It was felt that a comb...

ea0072p12 | (1) | UKINETS2020

A new diagnosis of both a pituitary TSH-oma and a metastaticneuroendocrine tumour

Boharoon Hessa , Ansari Mustafa Al , Sharma Rohini , Bravis Vasiliki , Wernig Florian

We report a new diagnosis of a pituitary TSH-oma together with a metastaticneuroendocrine tumour. A 61 year old man presented with a 3-year history of diarrhoea. His past medical history includes paroxysmal atrial fibrillation, for which he has had an ablation in the past. He takes no regular medications. Initial investigations were suggestive of hyperthyroidism in the context of unusual thyroid function test results (elevated freeT4 and freeT3 with elevated TSH). A pituitary ...

ea0096oc2 | Section | UKINETS2023

Interim analysis of Lantana: A phase Ib study to investigate epigenetic modification of somatostatin receptor-2 with ASTX727 to improve therapeutic outcome with [177Lu]Lu-DOTA-TATE in patients with metastatic neuroendocrine tumours (NCT05178693)

Rzeniewicz Karolina , Ward Caroline , Khan Sairah , Naik Mitesh , Barwick Tara , Aboayge Eric , Sharma Rohini

Background: Peptide-receptor-radionuclide-therapy (PRRT) improves progression free survival in metastatic neuroendocrine neoplasia (NEN). To be suitable for PRRT, somatostatin receptor-2 (SSTR2) must be present on tumour site as determined by positive uptake on [68Ga]Ga-DOTA-peptide-PET/CT. LANTana is an ongoing study evaluating whether treatment with the demethylating agent, ASTX727, results in re-expression of SSTR2, as determined by [68Ga]Ga-DOTA-peptide-PE...

ea0028oc5.5 | Growth, tumours and pituitary | SFEBES2012

Role of the hypoxic signalling pathways in the histopathological prediction of malignancy in phaeochromocytomas and paragangliomas

Pinato David , Ramachandran Radha , Toloue Kalami Toussi Samin , Vergine Marco , Ngo Nyethane , Sharma Rohini , Khoo Bernard , Meeran Karim , Palazzo Fausto , Martin Niamh , Dina Roberto , Tan Tricia

Backgeound and Aims: Phaeochromocytomas (PCC) and paragangliomas (PGL) are mostly benign sympathoadrenal tumours. However, there are no available markers to predict a malignant course. Since hypoxia is involved in the pathogenesis of these tumours, we aimed to qualify the relevance of the mammalian Target of Rapamycin (m-TOR) and hypoxic pathways in benign and malignant PCC/PGL.Methods: Tissue microarray (TMA) blocks were constructed with 80 PCC/PGL, inc...

ea0028p140 | Neoplasia, cancer and late effects | SFEBES2012

Expression of Somatostatin Receptors in Phaeochromocytoma and Paragangliomas

Parvizi Nassim , Alsafi Ali , Vergine Marco , Ramachandran Radha , Martin Niamh , Palazzo Fausto , Pinato David , Sharma Rohini , Meeran Karim , Dina Roberto , Tan Tricia

Background and Aims: Phaeochromocytoma and paragangliomas are neuroendocrine tumours arising from chromaffin cells. These tumours express somatostatin receptors (SSTRs), which has five different main subtypes (SSTR1, SSTR2, SSTR3, SSTR4 and SSTR5). The differential expression of the different receptor subtypes in these tumours has previously been reported with a small series of tumour samples. Our study examined the expression of SSTR subtypes in a larger series of benign and ...